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Risk factors associated with alterations in carotid
intima–media thickness in hypertension: baseline data 
from the European Lacidipine Study on Atherosclerosis
Alberto Zanchettia, M. Gene Bondb, Michael Hennigc, Albrecht Neissc,
Giuseppe Manciaa,d, Cesare Dal Palùe, Lennart Hanssonf, Bruno Magnanig,
Karl-Heinz Rahnh, John Reidi, Josè Rodicioj, Michel Safark, Lothar Eckesl
and Raffaella Ravinettom on behalf of the ELSA investigators
Background The possibility that calcium antagonists
exert an anti-atherosclerotic action at least partly
independently of the blood-pressure-lowering effect is
supported by results of a large number of experimental
studies and can now be investigated by quantitative 
B-mode ultrasound imagining of the carotid artery walls.
Design The European Lacidipine Study on
Atherosclerosis (ELSA) is a prospective, randomized,
double-blind, multinational trial comparing effects of 
4-year treatment based on the long-acting, highly
lipophilic calcium antagonist lacidipine with those of
treatment based on the b-blocker atenolol on the
development of carotid artery wall alterations in patients
(aged 45–75 years) with mild-to-moderate hypertension
(systolic blood pressure 150–210 mmHg and diastolic
blood pressure 95–115 mmHg). While the intervention
study is progressing, this article summarizes baseline
data obtained from the whole cohort of 2259 patients
randomly allocated to treatment.
Methods Baseline ultrasound data were obtained from
two replicate examinations performed shortly before
random allocation to treatment by certified sonographers
at 23 referral centres and read at the ultrasound
coordinating centre at the Wake Forest University School
of Medicine. Intima–media thickness was measured at up
to 12 different sites in the carotid artery tree and
expressed as the mean of the maxima at these sites
(Mmax), the mean of the maxima at four sites in the distal
common carotid artery and bifurcation (CBMmax) and the
maximum intima–media thickness (Tmax). Baseline
demographic and clinical measurements were performed
by investigators in 410 peripheral clinical units and 24 h
ambulatory blood pressure monitorings read and
validated by members of a centralized unit at the
University of Milan. The statistical analysis centre at the
Technische Universität München received and analysed
all baseline data, by calculating means ± SD, medians
and ranges and performing correlation (Spearman
correlation coefficients) and multiple regression analyses.
Results Prevalence of carotid artery wall alterations
among the hypertensive patients randomly allocated to
treatment in the ELSA was very high: 82% had
Tmax > 1.3 mm (‘plaques’ according to protocol) and 17%
had Tmax > 1.0 and < 1.3 mm (‘thickening’), with a median
of two plaques per patient. We found significant
correlations between ultrasound measurements and the
following demographic and clinical variables: age, sex,
systolic blood pressure and pulse pressure (both clinic
and ambulatory), concentrations of total, high-density
lipoprotein and low-density lipoprotein cholesterol and
triglycerides, smoking habit and duration of hypertension.
We found no significant correlation to diastolic blood
pressure and glucose concentration. A multiple
regression analysis indicated significant variables in the
following rank order: age, 24 h ambulatory pulse
pressure, sex, low-density lipoprotein cholesterol
concentration, triglyceride concentration, smoking and
clinic systolic blood pressure.
Conclusions Analysis of baseline data from the ELSA
has shown that there is an extremely marked prevalence
of carotid artery wall alterations among mild-to-moderate,
middle-aged hypertensive patients. In addition to age,
systolic blood pressure and pulse pressure, particularly if
they are accurately measured by ambulatory monitoring,
play a major role, somewhat greater than those of sex,
low-density lipoprotein cholesterol concentration and
smoking, in influencing intima–media thickness. 
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Introduction
Background and rationale of the European Lacidipine
Study on Atherosclerosis (ELSA)
Many randomized trials have now provided very
convincing evidence that antihypertensive therapy does
effectively lower the incidence of hypertension-related
cardiovascular events [1–3], but it has been remarked that
event-based trials, although they are fundamental in
demonstrating benefits of antihypertensive therapy,
cannot bring forth information on the ability of this
therapy to influence various types of cardiovascular injury
preceding and underlying events [4].
The possibility that antihypertensive drugs, or at least a
few classes of antihypertensive drugs, in particular calcium
antagonists and angiotensin converting enzyme inhibitors,
exert an anti-atherosclerotic action that is at least partly
independent of the blood-pressure-lowering effect is sup-
ported by a large body of evidence obtained from several
experimental models of atherosclerosis [5]. Quantita-
tive B-mode ultrasound imaging has recently been shown
to be a valid, sensitive and reproducible non-invasive
method for assessing morphological changes in the carotid
artery wall known to be associated with early atheroscler-
osis [6,7]. It has been used in two randomized trials, both
comparing a calcium antagonist with a diuretic agent. The
two trials, of a relatively small size, have led to appar-
ently different conclusions,  one, the Multicenter Isra-
dipine Diuretic Atherosclerosis Study (MIDAS, with 883
hypertensive patients), that the calcium antagonist isra-
dipine and the diuretic hydrochlorothiazide have a very
similar effect on progression of carotid artery wall lesions
[8], the other, the Verapamil Hypertension Atherosclerosis
Study (VHAS, with 494 hypertensive patients), that the
calcium antagonist verapamil had a significantly greater
influence than did the diuretic chlorthalidone on regres-
sion of carotid artery wall lesions [9].
ELSA [10,11] has been planned as a much larger random-
ized study using the same ultrasound methodology;
furthermore, the calcium antagonist chosen for random-
ized comparison with the b-adrenergic blocker atenolol 
is lacidipine, a slow-onset, long-acting, highly lipophilic
dihydropyridine, that has been shown to be quite effec-
tive in retarding progression of atherosclerosis lesions in
several experimental models [12].
Design, objectives, and organization of ELSA
These have more extensively been reported in previous
publications [10,11,13–17] and will be summarized here
insofar as they are relevant to the present article describ-
ing baseline characteristics of all subjects randomly
allocated to treatment in ELSA. In brief, ELSA is a
prospective, randomized, double-blind, multinational trial
comparing effects of 4-year treatment based on the
calcium antagonist lacidipine with those of treatment
based on the b-blocker atenolol on the development of
carotid artery wall alterations in patients with mild-to-
moderate hypertension.
We included in our study subjects of both sexes, aged
45–75 years, with sitting systolic blood pressure (SBP)
150–210 mmHg and diastolic blood pressure (DBP) 
95–115 mmHg, fasting serum total cholesterol concen-
tration < 320 mg/dl, fasting serum triglyceride concentra-
tion < 300 mg/dl, serum creatinine concentration < 1.7
mg/dl and a readable ultrasound carotid artery scan 
with maximum intima–media thickness (IMT) no greater 
than 4.0 mm. The main exclusion criteria were a recent
myocardial infarction or stroke and insulin-dependent
diabetes mellitus.
Double-blind randomized treatment with lacidipine was
initiated with a dose of 4 mg once daily, and brought to
6 mg once daily if, after 1 month, DBP had not been
lowered to < 90 mmHg; the initial dose of atenolol was
50 mg once daily, to be brought to 100 mg once daily 
if DBP had not been lowered to < 90 mmHg. Subse-
quently, if this DBP goal had not been attained, 12.5–
25 mg hydrochlorothiazide once daily could be added.
Randomly allocated treatment is to be maintained for a
minimum period of 4 years.
Before randomization and subsequently every year two
replicate B-mode ultrasound scans of the carotid arteries
and 24 h blood pressure monitoring are to be performed
at 23 referral centres, as detailed in Methods.
Patients were recruited by 410 clinical units in seven
European countries (France, Germany, Greece, Italy,
Spain, Sweden and UK). These units also perform clinic
measurements of sitting blood pressure and heart rate and
clinical examination of all subjects at 6-month intervals
throughout the trial. All forms with clinical and labora-
tory data are collected by monitors and sent to a data
management centre, responsible for the continuous deliv-
ery of data to the statistical analysis centre at the Institute
of Medical Statistics and Epidemiology, Technische
Universität, Munich, Germany, which also analyses all
data received from the ultrasound centre and the central-
ized ambulatory blood pressure calculation unit.
The primary objective of ELSA is a comparison of the
effects of the two randomly allocated treatments on
changes in carotid artery IMT during 4 years. A secondary
objective is to compare the effects of the two treatments
on the incidence of major cardiovascular events. The
primary end point for treatment efficacy analysis is the
change in the carotid IMT, measured as the mean of 
the maximum IMT of the four far walls of the carotid
bifurcations and distal common carotid arteries (defined
as CBMmax). Changes in the mean thickness of up to 12
different sites (right and left, near and far walls, distal
common, bifurcation and proximal internal carotid,
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defined as Mmax), in the overall mean maximum IMT
(defined as Tmax) and in the segment with the greatest
change elicited by treatment will also be analysed as
secondary end points. Final efficacy analyses will be
conducted without stratification of patients and baseline
IMT will be used as a covariate. The calculation of sample
size required was based on the following assumptions:
change in CBMmax, a = 5%, power 90%, d = 0.04 mm/year,
s = 0.1939 mm and drop-out rate 35%. This calculation
resulted in a total number of 1520 patients (760 patients
for each treatment) to be randomly allocated. A decision
to increase the sample size to at least 2000 patients was
taken in order to increase the statistical power of the final
analysis. In the present article we report baseline data
obtained from all randomly allocated patients and corre-
lation analyses performed with particular attention to all
IMT measurements considered end-points in the ELSA
protocol.
Methods
Ultrasound examinations
Details on the protocols for ultrasound examinations and
readings in ELSA have been reported elsewhere [15]. All
baseline data described here were obtained from two
replicate examinations performed between visits 0 and 1
by certified sonographers at 23 referral centres and read
at the ultrasound coordinating centre at the Division of
Vascular Ultrasound Research of the Wake Forest Univer-
sity Medical Center, Winston Salem, North Carolina,
USA. They have been expressed as CBMmax, Mmax and
Tmax, according to the definitions given above, and calcu-
lated as averages of two replicate measurements. Tmax
values have also been used to categorize patients into
three strata [stratum I (plaques) Tmax > 1.3 mm, stratum
II (thickening) Tmax < 1.3 mm but > 1.0 mm and stratum
III (normal) Tmax < 1.0 mm] and to identify the number
and location of IMT > 1.3 mm (‘plaques’) in various
segments of the carotid artery tree. IMT averages have
also been calculated for various carotid segments.
Demographic and clinical measurements
Before random allocation to treatment of patients (visits
0–1) investigators in peripheral clinical units completed
standard forms indicating the patient’s initials, sex, age
(years), race, weight (kg), height (m), estimated duration
of hypertension (years), smoking habits (smoker, former
smoker or non-smoker), relevant past medical history
(cardiovascular and non-cardiovascular), previous anti-
hypertensive medication (withdrawn at visit 0) and con-
comitant medication (at visit 0 and, separately, at visit 1).
Body mass index (BMI) was calculated as weight/height2.
During visit 1, after a 4-week wash-out from previous
antihypertensive medication and immediately before ran-
dom allocation to treatment, sitting clinic blood pressure
was measured by using a mercury manometer three
consecutive times during no less than 5 min after the
patients had been seated comfortably for at least 5 min.
The average of these three measurements was used for
further analyses. Pulse pressure was calculated as the
difference between SBP and DBP. Heart rate was calcu-
lated from the radial pulse during 30 s. Serum con-
centrations of creatinine, glucose, total cholesterol,
high-density lipoprotein (HDL) cholesterol and triglyc-
erides were measured from blood samples drawn during
visit 0; measurements (in mg/dl) were performed accord-
ing to standard laboratory methods in peripheral labora-
tories near the clinical units. Low-density lipoprotein
(LDL) cholesterol concentration was calculated according
to the standard formula and LDL : HDL ratio was also
calculated.
Ambulatory blood pressure monitoring
Baseline data were obtained from 25 h monitoring
performed after a period of wash-out from previous anti-
hypertensive medication before random allocation to
treatment, using the techniques described before [17].
Diskettes with patients’ recordings were edited at the
centralized ambulatory blood pressure calculation unit at
the Centro di Fisiologia Clinica e Ipertensione, University
of Milan, Ospedale Maggiore, to remove artefacts accord-
ing to criteria that had been determined beforehand [18]
and to verify completeness and quality of the monitored
data. Computer programs were used to obtain average
24 h, daytime (0600–0000 h) and night-time (0000–
0600 h) values for each of SBP, DBP, pulse pressure and
heart rate.
Statistical analysis
For all demographic, clinical, laboratory, blood pressure
(clinic and ambulatory) and carotid ultrasound data
means ± SD or medians (ranges) were calculated for data
from all evaluable patients. For non-continuous variables
frequency distributions were provided. There were two
baseline ultrasound measurements for each patient. The
average of these measurements was used for further
analyses. In particular, for categorization into strata, a
patient was considered to have a plaque if the average of
the two Tmax values was > 1.3 mm; the number of plaques
per patient was calculated by counting the sites with
maximum IMT > 1.3 mm, both for the first and for
second measurement, and averaging the results. Correla-
tion analyses were separately performed for relationships
between ultrasound data (expressed as CBMmax, Mmax,
mean Tmax and number of plaques per patient) and various
blood pressures and demographic and laboratory variables
usually considered risk factors for cardiovascular disease.
Correlations were also calculated for relationships between
serum metabolic variables and blood pressure values.
Correlations were expressed as Spearman correlation coef-
ficients and P values were calculated. Age-adjusted partial
correlation coefficients were also calculated. IMT meas-
urements for various subgroups, defined by sex, smoking
habit and previous cardiovascular diagnoses (yes/no) were
analysed. The differences between the groups were
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assessed by using non-parametric tests (Wilcoxon test for
two independent groups and Kruskal–Wallis test for more
than two independent groups).
Multiple regression analyses were performed separately
for the three key variables CBMmax, Mmax and Tmax. A set
of independent variables was identified with age, sex,
BMI, smoking status, previous antihypertensive medica-
tion, previous cardiovascular diagnoses, clinic SBP, DBP
and heart rate, the SBP–heart rate product, 24 h ambula-
tory SBP, DBP, pulse pressure and heart rate and serum
total cholesterol concentration, HDL cholesterol concen-
tration, LDL cholesterol concentration, LDL : HDL
cholesterol ratio, triglyceride concentration, glucose
concentration and creatinine concentration. In a first step
a simple analysis for correlation of the independent vari-
ables was performed and classes of variables with high
correlations were identified. By selecting a representative
of each of the classes the problem of multicollinearity was
avoided. This procedure resulted in the selection of the
variables age, sex, smoking status, BMI, glucose concen-
tration, LDL cholesterol concentration, HDL cholesterol
concentration, triglyceride concentration, 24 h ambulatory
pulse pressure and heart rate, clinic SBP, creatinine
concentration, previous antihypertensive medication and
previous cardiovascular diagnoses (yes/no). These were
used for a backwards elimination strategy, resulting in
identification of those variables with P values < 0.05.
Finally, the significant independent variables were
ordered according to their standardized effect, defined as
regression coefficient/standard error of the regression
coefficient. Multiple regression analyses were performed
using original values of IMT variables, after logarithmic
transformation and after transformation of CBMmax and
Mmax to 1/ÃCBMmax and 1/ÃMmax, the latter transformation
giving normally distributed values. In addition to the
multiple regressions based on the data from patients for
whom we had complete information on all variables
(complete case analyses), two strategies were also de-
ployed to handle missing values of the independent vari-
ables. In the first strategy missing values were substituted
by the corresponding mean of the variable; in the second
strategy by estimation of the independent variable from
the remaining independent variables. As mentioned
before, multiple tests were performed: the corresponding
P values have to be handled with care and interpreted
cautiously because no formal multiple test procedure was
used to control the overall level of significance.
Results
Recruitment of hypertensive patients for the ELSA trial
began in June 1994 and ended in November 1995, after
2259 subjects had been allocated randomly to treatment.
Demographic and clinical characteristics at baseline
These are summarized in Tables 1 and 2. In Table 1
prevalence of non-continuous variables is indicated as
number and percentage of patients with a given charac-
teristic. In Table 2 means and SD are listed for contin-
uous variables. Of our patients, 54% were men, almost all
were Caucasian and 21% were current smokers (Table 1).
Few had a history of cardiovascular disease (n = 289,
12.8%) and only 55 of these 289 patients reported having
previously suffered from major cardiovascular disease
(myocardial infarction, angina pectoris, a stroke, coronary
bypass surgery or angioplasty, congestive heart failure and
peripheral arterial disease). Of the randomly allocated
patients, 62.4% had previously been administered anti-
hypertensive therapy that was withdrawn at visit 0; less
than 10% had maintained some concomitant (non-anti-
hypertensive) medication at random allocation to treat-
ment. Patients had a mean age of 56 years (14.5% of
patients were older than 65 years), were moderately over-
weight (but only 20.6% had BMI > 30 kg/m2) and had
moderately elevated sitting SBP and DBP (164/101
mmHg; Table 2). At random allocation to treatment
previously treated patients (from whom therapy had 
been withdrawn for at least 4 weeks) had slightly higher
SBP (but not DBP) values than did previously untreated
patients. Ambulatory blood pressure values were available
for 1891 subjects (83.7% of all randomly allocated
patients). Twenty-four-hour average SBP and DBP values
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Table 1 Baseline patient characteristics: non-continuous
variables
All patients 2259 (100)
Countries of recruitment
France 342 (15.1)
Germany 425 (18.8)
Greece 129 (5.7)
Italy 797 (35.3)
Spain 131 (5.8)
Sweden 260 (11.5)
UK 175 (7.8)
Men 1225 (54.2)
Race
Caucasian 2218 (98.4)
Non-Caucasian 35 (1.6)
Smoking habit
Non-smoker 1263 (56.4)
Former smoker 509 (22.7)
Smoker 468 (20.9)
Medical history
Cardiovascular 289 (12.8)
Non-cardiovascular 1311 (58.0)
Major cardiovascular 55 (2.4)
Previous antihypertensive therapy
Diuretics 82 (3.6)
b-Blockers 238 (10.5)
Antihypertensives including ACE inhibitors 363 (16.1)
Vasodilators including calcium antagonists 298 (13.2)
Others 5 (0.2)
Combination therapy 422 (18.7)
None 851 (37.7)
Concomitant medication
Visit 0 876 (38.8)
Visit 1 (random allocation) 213 (9.4)
Values are expressed as numbers of patients (percentages). Data were
obtained during visit 0 (beginning of placebo run-in period) for patients
subsequently randomly allocated treatment (at visit 1). Previous antihyperten-
sive therapy indicates patients from whom antihypertensive therapy was
withdrawn at visit 0. Concomitant medication indicates patients being
administered non-antihypertensive therapy at visit 0 and, separately, at visit 1.
ACE, angiotensin converting enzyme.
were consistently lower than clinic sitting SBP and DBP,
with daytime values definitely higher than night-time
values. Metabolic data were available for 83–99% of
randomly allocated patients: means and SD are indicated
in Table 2. Overall 25.7% of subjects had total choles-
terol concentrations higher than 250 mg/dl, 3.1% had
HDL cholesterol concentrations lower than 30 mg/dl,
35.3% had LDL cholesterol concentrations higher than
160 mg/dl, 15.1% had triglyceride concentrations higher
than 200 mg/dl, and 7.4% had fasting glucose concentra-
tions higher than 120 mg/dl.
Ultrasound carotid artery wall measurements at 
baseline
The means, SD, medians and ranges of baseline values
of the IMT parameters used as major end points in ELSA
(CBMmax, Mmax and Tmax) are indicated in Table 3. As
expected, the mean of up to 12 sites (Mmax) gives the
lowest value and an intermediate value is calculated for
the mean of four sites in the bifurcation and distal
common carotid arteries (CBMmax), whereas the highest
value is obviously found for Tmax. The distributions of
CBMmax, Mmax and Tmax values are shown as histograms
in Figure 1.
Figure 2 indicates the distribution of patients among the
three strata defined according to the ELSA protocol. The
very high prevalence (82%) of Tmax > 1.3 mm (defined as
‘plaques’ according to the protocol) is evident, as is the
low number of patients (n = 22, 1%) with normal carotid
artery wall thicknesses (defined as Tmax < 1.0 mm). The
means of IMT measurements at common carotid and
internal carotid sites were lower than that of measure-
ments at the bifurcation (P = 0.0001, Wilcoxon test for
dependent samples; Table 3). Overall the total number
of discrete IMT measurements > 1.3 mm (plaques) for
randomly allocated patients was 3721, with a median of
two plaques per patient (range 0–11.5). The plaques were
mostly found within the bifurcation (79.9%), then the
internal (43.2%) and the distal common (36.7%) carotid
arteries. Of randomly allocated patients, 18% had no
plaque, 18% had one plaque only, 18% had two plaques,
15% had three plaques and 31% had more than three
plaques.
Correlation of baseline carotid artery measurements to
demographic and clinical characteristics of patients
Correlation coefficients for relationships between baseline
carotid artery IMT measurements and numbers of plaques
per patient and various demographic and clinical charac-
teristics of patients are listed in Table 4. In general the
highest correlation coefficients were found when Mmax
(mean of measurements up to 12 sites) was used, but
similar coefficients were also found when CBMmax (mean
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Table 2 Baseline patient characteristics: continuous variables
Variable Patients (n) Value
Age (years) 2251 56.1 ± 7.8
BMI (kg/m2) 2249 27.2 ± 3.8
Duration of hypertension (years) 1829 7.0 ± 6.3
Clinic sitting blood pressure and heart rate
SBP (mmHg) 2258 163.6 ± 12.6
DBP (mmHg) 2258 101.3 ± 5.3
Pulse pressure (mmHg) 2258 62.3 ± 11.5
SBP, previously treated (mmHg) 1408 164.5 ± 12.4
SBP, previously untreated (mmHg) 817 162.2 ± 12.9
DBP, previously treated (mmHg) 1408 101.3 ± 5.2
DBP, previously untreated (mmHg) 817 101.4 ± 5.4
Heart rate (beats/min) 2254 76.2 ± 9.2
Ambulatory blood pressure and heart rate
24 h SBP (mmHg) 1891 141.0 ± 14.5
24 h DBP (mmHg) 1891 87.9 ± 9.5
24 h pulse pressure (mmHg) 1891 53.1 ± 10.0
24 h heart rate (beats/min) 1891 74.2 ± 9.0
Serum concentrations (mg/dl)
Total cholesterol 2077 224.9 ± 38.4
HDL cholesterol 1882 51.3 ± 16.7
LDL cholesterol 1870 147.2 ± 36.1
LDL : HDL cholesterol ratio 1870 3.2 ± 1.4
Triglycerides 2061 135.1 ± 69.5
Glucose 2240 96.4 ± 20.4
Creatinine 1941 1.0 ± 3.1
Values are expressed as means ± SD of variables determined during visit 0
(beginning of placebo run-in period) namely age, body mass index (BMI),
duration of hypertension and metabolic variables, during visit 1 (clinic blood
pressure and heart rate) or between visits 0 and 1 (ambulatory blood
pressure and heart rate). Individual clinic blood pressure values are averages
of three consecutive measurements, individual ambulatory blood pressure and
heart rate values are averages of all measurements performed during 24 h. n,
the number of patients for whom a given measurement was available; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein.
Table 3 Baseline patient characteristics: ultrasound variables
Mean SD Median Range
CBMmax (mm) 1.20 0.26 1.15 0.65–2.83
Mmax (mm) 1.13 0.21 1.10 0.70–2.12
Tmax (mm) 1.80 0.58 1.67 0.88–4.83
IMT common carotids (mm) 1.04 0.17 1.02 0.67–2.10
IMT bifurcations (mm) 1.32 0.31 1.27 0.65–3.09
IMT internal carotids (mm) 1.02 0.28 0.95 0.43–3.19
Number of plaques per patient 2 0–11.5
Duplicate baseline measurements in 2259 patients, performed prior to random allocation to treatment
between visits 0 and 1. IMT, average intima–media thickness of measurements performed at the level of
the distal common carotid, bifurcation and proximal internal carotid arteries, bilaterally; CBMmax, mean of
the maximum of IMT of the four far walls of the carotid bifurcations and distal common carotid arteries;
Mmax, changes in the mean thickness of up to 12 different sites (right and left, near and far walls, distal
common, bifurcation and proximal internal carotid); Tmax, overall mean maximum IMT.
of common and bifurcation measurements) was used.
Correlation coefficients calculated for Tmax (measurement
at a single site) were somewhat lower. Correlation coef-
ficients calculated for number of plaques per patient were
generally intermediate between those calculated for Mmax
and those calculated for Tmax. The strongest associations
were found for age, but highly significant correlations were
also evident for SBP and pulse pressure, both when clinic
and when 24 h ambulatory values were considered.
Ambulatory values generally resulted in higher correla-
tion coefficients. We found no significant correlation with
DBP (either clinic or ambulatory values). For heart rate
we found a statistically significant negative correlation to
IMT measurements only when 24 h ambulatory values
were considered. All lipid concentration measurements
were correlated to carotid measurements (HDL in a nega-
tive way) but there was no significant correlation to
glucose concentration and BMI. Correlations to creatinine
concentration were of borderline significance. We found
low, but statistically significant, correlations between
duration of hypertension and carotid IMT.
Partial correlation coefficients were also calculated after
adjustment for age. After adjustment for age, the corre-
lations to duration of hypertension were no longer signif-
icant. Correlation coefficients for clinic SBP and pulse
pressure were markedly reduced (from 0.20 to 0.12 and
from 0.22 to 0.12 for Mmax) though still remained highly
significant. Correlation coefficients for ambulatory SBP
and pulse pressure were also decreased by adjusting for
age, but to a lesser degree (from 0.24 to 0.21 for 24 h SBP
and from 0.35 to 0.23 for 24 h pulse pressure for Mmax).
Correlations for serum lipid concentrations were only
slightly influenced by adjusting for age.
Correlations of carotid IMT measurements to non-
continuous variables for patients were determined by
calculating means and SD of CBMmax for stratified groups
of patients. There was a clear influence of sex, in that
men had CBMmax of 1.23 ± 0.26 mm and women had
1.16 ± 0.24 mm (P = 0.0001). Stratifying by smoking habit
gave CBMmax values of 1.17 ± 0.25 mm in non-smokers,
1.21 ± 0.25 mm in smokers and 1.24 ± 0.28 mm in former
smokers (P = 0.0001). Patients with previous cardiovas-
cular diagnoses had CBMmax of 1.22 ± 0.26 mm, those with
a non-cardiovascular diagnosis or no diagnosis had
1.19 ± 0.26 mm (P = 0.0891).
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Distributions of baseline values of the means of the maximum
intima–media thickness (IMT) of the four far walls of the carotid
bifurcations and distal common carotid arteries (CBMmax, a), of the
means of the maximum IMT at up to 12 sites (right and left, near and
far walls, distal common, bifurcation and proximal internal carotid,
Mmax, b) and of the overall maximum IMT (Tmax, c) for the entire
population of patients randomly allocated to treatment in ELSA
(n = 2259).
Fig. 1
1860
82.34%
22
0.97%
377
16.69%
Distribution of all patients randomly allocated to treatment in 
ELSA (n = 2259) among the three strata according to protocol
(black area, plaque, patients with baseline Tmax > 1.3 mm; grey area,
thickening, patients with baseline Tmax = 1.0–1.3 mm; white area,
normal, patients with baseline Tmax < 1.0 mm). Total numbers and
percentages of patients by stratum are indicated.
Fig. 2
Multiple regression analyses were performed as described
in Methods. Reverse elimination by deleting variables
with P > 0.05 gave the results shown in Table 5. The data
in Table 5 refer to 1544 (1537 for Tmax) patients (68% 
of all patients) for whom we had complete data on the
variables selected. The analyses of Table 5 were per-
formed on original values of IMT variables, without trans-
formation. Age had the highest standardized effect, then
24 h ambulatory pulse pressure, then sex and then LDL
cholesterol concentration. Triglyceride concentration,
clinic SBP and smoking habits had lower standardized
effects. On the whole, R2 values were 0.179 for CBMmax,
0.235 for Mmax and 0.123 for Tmax for the patient popula-
tion of Table 5.
Logarithmic transformation of IMT variables left the 
rank of all risk factors unchanged. Transformation to
1/ÖCBMmax and 1/ÖMmax again left the rank of the four
major factors unmodified, but clinic SBP lost significant
correlation, in favour of HDL cholesterol concentration.
When the two strategies for substitution of missing 
values, mentioned in Methods, were implemented and
multiple regression analyses recalculated for populations
of 2240 and 1998 patients, respectively, the rank of the
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Table 4 Correlative baseline data: carotid versus demographic and clinical measurements
Number of plaques 
CBMmax Mmax Tmax per patient
r Significance r Significance r Significance r Significance
Age 0.35 P = 0.0001 0.37 P = 0.0001 0.28 P = 0.0001 0.32 P = 0.0001
Body mass index 0.03 NS 0.04 NS 0.02 NS 0.01 NS
Duration of hypertension 0.09 P = 0.0026 0.12 P = 0.0001 0.07 P = 0.0159 0.09 P = 0.0019
Clinic SBP 0.19 P = 0.0001 0.20 P = 0.0001 0.13 P = 0.0001 0.16 P = 0.0001
Clinic DBP -0.03 NS -0.04 NS -0.05 NS -0.05 NS
Clinic pulse pressure 0.21 P = 0.0001 0.22 P = 0.0001 0.16 P = 0.0001 0.18 P = 0.0001
Clinic heart rate -0.05 NS -0.05 NS -0.04 NS -0.04 NS
24 h ambulatory SBP 0.23 P = 0.0001 0.24 P = 0.0001 0.18 P = 0.0001 0.21 P = 0.0001
24 h ambulatory DBP 0.03 NS 0.02 NS 0.02 NS 0.03 NS
24 h ambulatory pulse pressure 0.32 P = 0.0001 0.35 P = 0.0001 0.25 P = 0.0001 0.29 P = 0.0001
24 h ambulatory heart rate -0.11 P = 0.0001 -0.13 P = 0.0001 -0.07 P = 0.0229 -0.10 P = 0.0007
Total cholesterol concentration 0.10 P = 0.0005 0.12 P = 0.0001 0.10 P = 0.0009 0.11 P = 0.0002
HDL cholesterol concentration -0.08 P = 0.0051 -0.11 P = 0.0001 -0.09 P = 0.0030 -0.10 P = 0.0003
LDL cholesterol concentration 0.11 P = 0.0001 0.14 P = 0.0001 0.12 P = 0.0001 0.13 P = 0.0001
LDL : HDL cholesterol ratio 0.13 P = 0.0001 0.17 P = 0.0001 0.13 P = 0.0001 0.15 P = 0.0001
Triglyceride concentration 0.08 P = 0.0038 0.10 P = 0.0004 0.07 P = 0.0209 0.09 P = 0.0020
Glucose concentration -0.02 NS -0.00 NS -0.00 NS -0.02 NS
Creatinine concentration 0.05 NS 0.08 P = 0.0038 0.07 P = 0.0209 0.06 NS
Spearman correlation coefficients and P values for variables in Tables 2 and 3. Calculations are based on data from 1173 patients for whom complete sets of
data were available. SBP, systolic blood pressure; DBP, diastolic blood pressure; CBMmax, mean of the maximum of IMT of the four far walls of the carotid
bifurcations and distal common carotid arteries; Mmax, changes in the mean thickness of up to 12 different sites (right and left, near and far walls, distal
common, bifurcation and proximal internal carotid); Tmax, overall mean maximum IMT.
Table 5 Multiple regression analyses of baseline carotid ultrasound measurements from demographic and clinical data
for patients for whom complete sets of data were available
Standardized effecta Significance (P )
Variable CBMmax Mmax Tmax CBMmax Mmax Tmax 
(n = 1544) (n = 1544) (n = 1537) (n = 1544) (n = 1544) (n = 1537)
Age 9.44 10.62 7.41 0.0001 0.0001 0.0001
24 h pulse pressure 6.95 8.10 6.25 0.0001 0.0001 0.0001
LDLC concentration 4.98 5.94 3.93 0.0001 0.0001 0.0001
Sex (male versus female) 4.80 7.44 5.00 0.0001 0.0001 0.0001
Triglyceride concentration 2.13 2.75 2.54 0.0331 0.0061 0.0110
Smoking
Smoker versus non-smoker 3.34 4.06 3.84 0.0011 0.0001 0.0002
Smoker versus former smoker 0.78 0.60 1.03
Clinic SBP 1.99 2.26 0.0472 0.024
Body mass index –2.09 0.0369
aRegression coefficient/standard error of regression coefficient; for categorical variables such as sex and smoking this is the effect of one
category related to another category (indicated in brackets). LDLC, low-density lipoprotein cholesterol; SBP, systolic blood pressure; CBMmax,
mean of the maximum of IMT of the four far walls of the carotid bifurcations and distal common carotid arteries; Mmax, changes in the mean
thickness of up to 12 different sites (right and left, near and far walls, distal common, bifurcation and proximal internal carotid); Tmax, overall mean
maximum IMT.
standardized effects of the variables remained substan-
tially the same as the one indicated in Table 5.
Correlations among metabolic variables, blood pressure
and heart rate
All correlations were low, less than 0.09, with the sole
exception of the correlation between 24 h ambulatory
DBP and plasma creatinine level (r = 0.15). Although the
level of statistical significance was occasionally attained,
no haemodynamic variable was consistently and signifi-
cantly correlated to all lipid variables. Magnitudes and
statistical significances of the various correlation coeffi-
cients are indicated in Figure 3.
Discussion
Baseline ultrasound and blood pressure data from the
ELSA cohort should be viewed as the set of initial data
for the planned comparison to be performed at the end
of this 4-year prospective interventional trial.
In that as many as 2259 hypertensive subjects have been
allocated randomly, the ELSA is the largest available
source of information about carotid artery wall alterations
in hypertensive patients. It is also the only study providing
a substantial amount of data on ambulatory blood pressure
measurement in hypertension.
Carotid artery IMT and cardiovascular risk factors
Among the various demographic and clinical characteris-
tics of ELSA patients, age has been found to have the
most consistent and strongest correlations to all measure-
ments of carotid IMT, confirming the importance of age
as a determinant of IMT that had already been reported
by authors of previous studies [19–24]. Significant corre-
lations of IMT to SBP [19,20,22–24], male sex [19,21,
23–25], cholesterol concentration [19,22–25], triglyceride
concentration [19], smoking [22–24] and previous cardio-
vascular disease [26] have also been reported. However,
one of the most important findings of ELSA baseline data
analyses is the important role played by blood pressure
in accounting for differences in carotid wall thickness. In
multiple regression analyses of the ELSA data a blood
pressure measure, 24 h ambulatory pulse pressure, always
ranked second to age, preceding in importance sex and
LDL cholesterol concentration. The importance of blood
pressure compared with that of LDL cholesterol concen-
tration in ELSA might reflect the fact that our popula-
tion was a selected one of hypertensive patients, and it
is conceivable that LDL cholesterol concentration would
have played a greater role for a population sample of
hypercholesterolaemic subjects. It is also likely that the
role of blood pressure could be studied better in ELSA
than in previous studies, because of our in-depth use of
ambulatory blood pressure monitoring, and because we
considered pulse pressure in addition to SBP and DBP.
In univariate correlation analyses the use of ambulatory
blood pressure measurements regularly yielded higher
associations with IMT than clinic blood pressure values
and pulse pressure always yielded higher relationships
than did SBP. In view of the importance traditionally
given to DBP in guidelines for management of hyper-
tension, it has to be noticed that DBP values in members
of the ELSA population, even when calculated from
ambulatory monitoring, had no relationship with carotid
IMT. 
Adjusting for age reduced correlation coefficients for 
SBP and pulse pressure, confirming the relationship of
SBP with age. Relationships of ambulatory SBP and pulse
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TCh
HDL
LDL
LDL/HDL
TG
G
Cr
CSBP CDBP CPP CHR 24hA–SBP 24hA–DBP 24hA–PP 24hA–HR
Spearman correlations of baseline metabolic variables to baseline blood pressure and heart rate. The size of each circle is proportional to the
correlation; full circle, positive correlation; dashed circle, negative correlation; grey circle, significant correlation. The blood pressure and heart
rate variables are indicated on the abscissae, the metabolic variables on the ordinates. TCh, total cholesterol concentration; HDL, high-density
lipoprotein cholesterol concentration; LDL, low-density lipoprotein cholesterol concentration; LDL/HDL, LDL : HDL ratio; TG, triglyceride
concentration, G, glucose concentration; Cr, creatinine concentration; CSBP, clinic systolic blood pressure; CDBP, clinic diastolic blood
pressure; CPP, clinic pulse pressure; CHR, clinic heart rate; 24hA-SBP, 24 h mean ambulatory systolic blood pressure; 24hA-DBP, 24 h mean
ambulatory diastolic blood pressure; 24hA-PP, 24 h mean ambulatory pulse pressure; 24hA-HR, 24 h mean ambulatory heart rate. From 1444
patients in whom complete baseline data were available.
Fig. 3
pressure values were less greatly reduced by adjusting for
age; this is consistent with data from the PAMELA study
[27], which showed that ambulatory SBP increases with
age to a lesser extent than does clinic SBP. 
In multiple regression analyses, 24 h ambulatory pulse
pressure maintained an important role, indicated by its
rank immediately after age and a standardized effects in
the range 6.25–9.01 (standardized effect of age was
7.41–14.09). Clinic SBP was also a significant variable in
multiple regression analyses, but with smaller standard-
ized effects (1.99–3.74). The stronger correlation of pulse
pressure than of SBP to carotid artery wall alterations
supports the hypothesis that the pulsatile components of
blood pressure have importance as a cardiovascular risk
factor [28,29].
Plasma lipid concentrations were all significantly corre-
lated to IMT measurements for the ELSA population,
the correlation being negative, as expected, for HDL
cholesterol concentration. The finding that adjustment for
age only slightly affected these associations confirms that
plasma lipid concentrations are hardly influenced by age,
at least in the age range of the ELSA patients [30]. In
multiple regression analyses LDL cholesterol concentra-
tion’s association was regularly maintained, whereas that
of triglyceride concentration was frequently retained but
with a relatively low standardized effect (maximum 2.75).
The standardized effect of LDL cholesterol level was in
the range 3.92–6.23, being only slightly lower than that
of sex (4.80–8.84). It is of some interest that plasma
glucose concentration was not found to correlate to carotid
IMT for the ELSA population, but uncontrolled diabetes
was an exclusion criterion. The observation that correla-
tions between serum creatinine concentration and carotid
IMT were of only borderline significance might have
resulted from the exclusion of subjects with serum crea-
tinine concentrations > 1.7 mg/dl.
In the multiple regression analyses smoking persisted as
a significant factor, though with standardized effects
slightly lower than those of sex and LDL cholesterol
concentration. It is interesting that there was no signifi-
cant difference in IMT between smokers and former
smokers. Previous antihypertensive therapy also did not
provide any significant contribution to the results of
multiple regression analysis. A history of previous cardio-
vascular disease had no significance as a risk factor in
multiple regression analyses. However, a history of major
cardiovascular disease was rare among ELSA patients
because of our exclusion criteria.
Results of three recent studies in Finland [22–24] are
consistent with the conclusions of our analysis of the
ELSA population, insofar as all of them indicate that age
is the most important predictor and SBP is a highly signif-
icant risk factor of carotid IMT.
Prevalence of carotid artery ‘plaques’ in hypertension
An interesting aspect of baseline observations in ELSA
is the high prevalence of thickenings > 1.3 mm, defined
as ‘plaques’ in the protocol. This was consistent
throughout recruitment, with the prevalence of patients
with ‘plaques’ in the range 82–83% when it was calcu-
lated after recruitment of 957, 1489, 1965 and 2259
patients. There was no great variation of prevalence
among referral centres, prevalence ranging from 72% in
Milan to 93% in Stockholm. ‘Plaques’ were more preva-
lent in the internal carotid and bifurcation than in distal
common carotids.
When correlations between number of ‘plaques’ in indi-
vidual patients and patients’ characteristics were studied,
we found significant associations with the same charac-
teristics as those correlated to IMT average measure-
ments, namely age, SBP and pulse pressure (however
measured), LDL cholesterol concentration and LDL :
HDL cholesterol ratio gave the highest correlation coef-
ficients.
The high prevalence of ‘plaques’ in the ELSA popula-
tion was not expected, since when the study was origi-
nally planned we had hypothesized that we would have
found a similar proportion of patients with ‘plaques’, of
patients with ‘thickenings’ and of patients with ‘normal’
carotids. Consequently, after recruitment of the first 1000
patients, a decision to redesign the study partially, by
avoiding analyses based on strata and using baseline IMT
measurements as continuous covariables, was taken.
Comparison of prevalence of ‘plaques’ in ELSA with
prevalences in other interventional and observational
studies is made difficult by the use of different defini-
tions of ‘plaque’. Among interventional trials, MIDAS
investigators used the same definition of ‘plaque’ as that
in ELSA, but the randomly allocated cohort was entirely
made up of subjects with ‘plaque’, for the occurrence of
‘plaque’ was a criterion for inclusion in the trial [31].
A more valid comparison of VHAS and ELSA baseline
data can be made, because in both studies patients were
selected on the basis of similar criteria independently of
the presence or absence of carotid wall alterations.
Baseline patient characteristics were similar, with some
higher SBP values (167.8 versus 163.6 mmHg) and slightly
lower predominance of men (51.2 versus 54.3%) in VHAS
than in ELSA. However, among VHAS subjects 39% of
patients had ‘plaques’, 27% of patients had thickenings
and as many as 34% of patients had normal carotid artery
walls [9]. The definition of plaques in VHAS was much
more conservative than that in ELSA (and than that in
MIDAS) insofar as ‘plaque’ was defined as IMT > 1.5 mm.
Indeed, if this criterion were applied to ELSA patients,
prevalence of plaque would decrease to 63.8%. This is a
good illustration of the effects of the arbitrary cut-off
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criteria that are necessarily used to define carotid
‘plaques’. The much lower percentage of patients with
‘normal’ carotid arteries in ELSA than in VHAS remains
unexplained, however. It is not due to geographical
factors: although ELSA was an international European
study and the VHAS a purely Italian study, the preva-
lence of carotid artery alterations among ELSA patients
recruited in Italy was similar to that among those recruited
in other European countries. It should be remarked,
however, that the upper limit of normality for IMT set
both in ELSA and in VHAS was rather high and that a
proportion of VHAS patients defined with ‘normal’
carotids was likely to have some wall thickening.
Comparing prevalence of ‘plaques’ in ELSA with data
from observational studies is difficult, because of different
definitions of ‘plaque’ used in other studies and different
characteristics of the examined populations. In most cases
an arterial plaque was defined as an echogenic structure
encroaching into the vessel lumen with a distinct area and
having an IMT more than 50% greater than that of neigh-
bouring sites. According to this definition, prevalence of
plaques among hypertensive patients was found to be
23–96%, according to patient characteristics [23,32–36]. In
most of these studies, age, history of hypertension, history
of smoking, cholesterol concentration and systolic blood
pressure were significantly correlated to number or extent
of plaques [23,32,36], supporting the data from ELSA. In
the Kuopio Ischaemic Heart Disease Risk Factor Study
[37] the prevalence of carotid plaques among men with
sitting SBP > 175 mmHg was 2.61-fold greater than that
among men with lower SBP. Likewise, in the Athero-
sclerosis Risk in Communities (ARIC) study [38] hyper-
tension was associated with an adjusted odds ratio for
ultrasound evidence of carotid atherosclerosis of 2.9 rela-
tive to normotensive individuals.
Are carotid artery wall alterations related to
atherosclerosis?
It appears quite interesting that, in the analysis of ELSA
baseline data, all major known risk factors for atheroscle-
rosis have been found to be correlated to the various IMT
measures used as end points in the trial and to the number
of ‘plaques’. However, current ultrasound techniques
cannot clearly distinguish between media and intima 
and all measurements reflect the intima–media complex.
At present it is not possible to determine whether an
increase in IMT is a result of medial hypertrophy and
thus represents carotid artery localization of a more wide-
spread hypertension-related phenomenon or whether it is
the expression of intima thickening, thus being an early
manifestation of atherosclerosis [39]. Although no definite
answer to this crucial question can be given at present,
the latter interpretation is favoured by the fact that thick-
enings are predominantly located in the bifurcation
(which is known to be the preferred site for atherosclerotic
lesions) and by the discrete nature of these thickenings,
which makes their definition as ‘plaques’ reasonable. The
correlation between carotid artery IMT and ‘plaques’ on
one side and coronary events and strokes on the other
found both retrospectively [19] and prospectively [40]
lends further support to the assumption that at least part
of the increase in IMT frequently found in hypertensive
patients is related to atherosclerosis.
Correlations between blood pressure values and
metabolic variables
The lack of consistently significant correlations between
blood pressure values (including ambulatory blood
pressure) and plasma lipid concentrations deserves a brief
comment, because this seems to be in contrast to a recent
analysis by Goode et al. [41] of data provided by a number
of large epidemiological studies in which some correla-
tions, particularly between SBP and total cholesterol and
triglyceride concentrations, have been found. As a matter
of fact, some occasional correlations, including those
between clinic SBP and pulse pressure and total choles-
terol concentration, have also been found for the ELSA
patients, but the observations that only ambulatory pulse
pressure and not ambulatory SBP maintained a significant
association with total cholesterol concentration and that
no blood pressure measurement was ever significantly
correlated to LDL cholesterol concentration injects some
reasonable doubt. However, most of the epidemiological
studies analysed by Goode et al. [41] were much larger
than ELSA and, furthermore, patients with serum total
cholesterol or triglyceride concentrations > 300 mg/dl
were excluded from ELSA. Likewise, the weakness of
the expected correlation between blood pressure values
and serum creatinine concentration might have resulted
from the exclusion of patients with serum creatinine
concentrations > 1.7 mg/dl.
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